An exciting recent approach to target transcription factors in cancer is to block formation of oncogenic complexes. Here we test whether interfering with the interaction of the transcription factor SALL4, which is critical for leukemic cell survival, and its epigenetic partner complex represents a novel therapeutic approach. The mechanism of SALL4 in promoting leukemogenesis is at least in part mediated by its repression of the tumor suppressor PTEN through its interaction with a histone deacetylases (HDAC) complex. In this study, we demonstrate that a peptide can compete with SALL4 in interacting with the HDAC complex and reverse its effect on PTEN repression. Treating SALL4expressing malignant cells with this peptide leads to cell death that can be rescued by a PTEN inhibitor. The anti-leukemic effect of this peptide can be confirmed on primary human leukemia cells in culture and in vivo, and is identical to that of down-regulation of SALL4 in these cells using an RNAi approach. In summary, our study demonstrates a novel peptide that can block the specific interaction between SALL4 and its epigenetic HDAC complex in regulating its target gene PTEN. Furthermore, targeting SALL4 by this approach could be an innovative approach in treating leukemia.
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Abstract:
An exciting recent approach to target transcription factors in cancer is to block formation of oncogenic complexes. Here we test whether interfering with the interaction of the transcription factor SALL4, which is critical for leukemic cell survival, and its epigenetic partner complex represents a novel therapeutic approach. The mechanism of SALL4 in promoting leukemogenesis is at least in part mediated by its repression of the tumor suppressor PTEN through its interaction with a histone deacetylases (HDAC) complex. In this study, we demonstrate that a peptide can compete with SALL4 in interacting with the HDAC complex and reverse its effect on PTEN repression. Treating SALL4expressing malignant cells with this peptide leads to cell death that can be rescued by a PTEN inhibitor. The anti-leukemic effect of this peptide can be confirmed on primary human leukemia cells in culture and in vivo, and is identical to that of down-regulation of SALL4 in these cells using an RNAi approach. In summary, our study demonstrates a novel peptide that can block the specific interaction between SALL4 and its epigenetic HDAC complex in regulating its target gene PTEN. Furthermore, targeting SALL4 by this approach could be an innovative approach in treating leukemia.
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From
Introduction:
Members of the SAL gene family belong to a group of C2H2 zinc finger transcription factors characterized by multiple zinc finger domains present in the protein 1, 2 . Sal is a non-clustered region-specific homeobox gene which plays an essential role in Drosophila, and Sal-related genes have been isolated from C. elegans 3 , fish 4 , frogs (xenopus) 5, 6 , mice 7 and humans 2 . Each of these homologues is expressed during embryonic development as well as in a more limited set of specific adult tissues. Murine Sall4 plays a crucial role in development as well. Sall4-null mice die at E6.5 [8] [9] [10] [11] . We have shown that murine Sall4 is essential for the maintenance of pluripotency and self-renewal properties of embryonic stem (ES) cells by interacting with two other key regulators in ES cells, Nanog and Oct4 11, 12 .
After birth, SALL4 expression is down-regulated and absent in most adult tissues. However, SALL4 is expressed in various cancers, including a subset (30%) of solid tumors, such as breast cancer 13 , ovarian cancer 14 , gastric cancer 15 , Wilms tumor 16 , and germ cell tumors 14, [17] [18] [19] [20] [21] , as well as in leukemias, most notably almost all cases of human acute myeloid leukemia (AML) 22 and about 75% of B cell acute lymphoblastic lymphoma/leukemia (B-ALL) 23 . We have also reported that SALL4 is enriched in the "side-population (SP)" of the leukemia and solid tumor cells. The SP is implicated in drug resistance and cancer initiation, and is used to isolate cancer initiation cells (CICs) 24 . SALL4 expression is correlated with worse prognosis in AML patients as well 24 .
For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From In addition, from various studies, we have shown that SALL4 has functional roles in leukemogenesis. Transgenic mice expressing SALL4 develop MDS and AML 22 . Loss of function studies have demonstrated that SALL4 is a key regulator of leukemic cell survival, and down-regulation of SALL4 can lead to significant apoptosis of leukemic cells in a cell line model 25 . We have recently characterized a "SALL4 leukemic initiation signature" in the transgenic murine model and found that SALL4 mainly acts as a repressor by interacting with the nucleosome remodeling and deacetylase (NuRD) complex that comprises HDAC1 and HDAC2. PTEN (phosphatase and tensin homolog deleted on chromosome 10), one of the factors that are essential for the self-renewal of LSCs 26 , is repressed by SALL4 through the NuRD, a HDAC complex 27 .
In this study, we test the hypothesis that blocking the SALL4/HDAC interaction would lead to a biological effect on cancer cells, in particular AML cells. We first demonstrated that the HDAC recruiting region of SALL4 contains 12 amino acids (AA). We then showed that this 12-AA peptide promotes growth inhibition of SALL4-expressing leukemic cells, similar to that observed following treatment with a classic HDAC inhibitor, trichostatin A (TSA), as well as following down-regulation of SALL4 by shRNA. The anti-tumor effect of this peptide can be rescued by a PTEN inhibitor.
These studies demonstrated a novel therapeutic strategy for inhibition of growth of tumor cells dependent on SALL4 pathways.
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Materials and Methods

Peptide synthesis, binding affinity and delivery assays
Peptides were synthesized by Biosynthesis Inc., Lewisville, Texas, using standard solid phace peptide synthesis chemistry and purified by the manufacturer typically to 95% purity. Peptides were dissolved in deionized 
Culture of primary AML samples
Three frozen primary AML patient samples were used for this study (Supplemental Table 1 ), and were obtained from Brigham and Women's Hospital at Boston, MA, USA, under approved IRB protocol (No. 2011-P-000096/1). This study was conducted in accordance with the Declaration of Helsinki. Culture conditions were adapted from a published protocol [29] [30] [31] [32] . In brief, the frozen AML samples were incubated in RPMI1640 medium without serum for 1 to 3 h after thawing and DNA fragments from dead cells were removed by washing. After three washes with the medium, 1x10 6 cells per well of 12-well plate were maintained in 1 ml of serum-free medium (StemSpan-H3000, Catalogue # 09800, StemCell Technologies) supplied with StemSpan CC100 cytokine cocktail (Catalogue # 02690, StemCell Technologies) that supports 40-50% viability at 72 hours post-thaw culturing based on our experience. These cells were then used for the down-regulation of SALL4 (see details below) and peptide treatment experiments.
Xenotransplantation NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, The Jackson Laboratory, ME, USA) mice were bred and maintained in the Children's Hospital Boston animal facility. All animal work has been approved by and done according to the guidelines of the IACUC under protocol 10-10-1832. Human primary AML cells exposed to various peptides or carrier only (1.0x10 6 cells per mouse) or transduced with SALL4-shRNA or control lentivirus (1.5x10 6 cell per mouse) were transplanted into 10-to 12-week old mice received 135 cGy sublethal irradiation 
Results:
A peptide derived from the amino terminal 12 amino acids sequence of
SALL4 interacts with the HDAC complex
We have previously shown that SALL4 interacts with NuRD 27 , and others have suggested that another SALL gene family member, SALL1, can recruit the NuRD complex through interaction with a conserved 12 amino acid sequence at its N-terminus [34] [35] [36] . As the N-termini of SALL1 and SALL4 are almost identical, we hypothesize that the N-terminus of SALL4 is involved in the recruitment of HDAC/NuRD (in this manuscript we refer to this 12 amino acid peptide at the Nterminus of SALL4 as wild type (wt)). It has been shown by others that mutating amino acids 3 to 5 of this 12-AA wt peptide abrogates its binding to the NuRD complex. Among these three amino acids, mutation of residue 5 (Lys) alone abolishes NuRD/HDAC interaction to the greatest extent 35,37,38 . Therefore, we mutated residue 5, converting Lys to Ala in the context of the 12 wt amino acid peptide, to act as a negative control (mut). A second negative control, scrambled peptide (scr), was designed with the same 12 amino acids as that of the wt peptide, but in a scrambled sequence. Designing the scrambled peptide in this manner can maintain the overall net charge of this peptide, which affects cellular uptake of the peptide ( Figure 1A ).
We first evaluated whether the wild type peptide or the mutant or scrambled controls could bind to HDAC1 and HDAC2, which comprise part of the nuclear extracts from SNU-398 cells pre-treated with FITC-labeled wild type, mutant, or scrambled peptides revealed that HDAC1 and HDAC2 could be easily detected in nuclear complexes obtained from the cells treated with wild type peptide. Much reduced HDAC binding to the mutant peptide was observed, and binding to the scrambled peptide was undetectable ( Figure 1B) . We further hypothesized that if the peptide interacted with HDAC1 and/or HDAC2, then the peptide pull-down could exhibit HDAC activity. To test this possibility, we measured the histone deacetylase activity of the peptide pull-down complex using a fluorescent assay kit ( Figure 1C ). The active enzymatic activity of the HDACs tested by this assay corresponded to the amount of the HDAC proteins in the sample. While the wild type peptide pull-down had the most HDAC activity and the mutant showed some residual activity, the scrambled peptide, which did not bind to HDAC, exhibited no HDAC activity in the pull-down, comparable to that observed with the IgG control.
We next tested the binding affinity of the wild type and scrambled peptides to the HDAC complex. For this, we used Fluorescent Polarization (FP), a technology based on molecular movement and rotation in which fluorescent molecules are excited with polarized light. If the fluorescent molecules are part of a large complex, they rotate less and the emitted light has high polarity. In contrast, smaller molecules rotate faster and have low polarity ("depolarized").
FP has long been a valuable biophysical research tool for investigating proteinprotein or peptide-protein interactions at the molecular level. When a fluorescent labeled peptide binds to a target protein or a complex, it becomes part of the large molecular complex and becomes less mobile and has high polarization.
However, excessive amount of unlabeled peptide added to the abovementioned mixture will displace the labeled peptide and the free labeled peptide will have low polarization. Using this approach, FITC-labeled wild type or scrambled peptides were first mixed with nuclear extracts from SNU-398 cells. Serial dilutions of unlabeled wild type or scrambled peptides were then added as competitors respectively, and measured by FP assay. While wild type peptide had an IC50 of 5µM, the IC50 for the scrambled peptide could not be calculated due to the lack of binding activity ( Figure 1D and Supplemental Figure 1 ). In summary, the 12 amino acid wild type peptide derived from the amino terminus of SALL4 can bind to an active HDAC complex.
The wild type peptide competes with endogenous SALL4 to block interaction with HDAC and repression of PTEN
We next tested the cellular uptake and localization of these peptides in various types of cells using FITC-labeled wild type or scrambled peptides.
Despite the net positive charge of these peptides, their penetration into cells is cell type-specific. Some cell lines, such as HL-60 (an AML cell line), allowed peptide entry without any modification or facilitator, while others such as SNU-398 were not penetrable at all. In order to achieve a similar level of peptide delivery across a range of cell types, we used a 21 amino acid residue peptide carrier, Pep-1 40 . The overall success rate of peptide uptake by the cells was above 95% with Pep-1, as evaluated by flow cytometry (Figure 2A ). In addition, confocal microscopic studies confirmed the uptake of these peptides throughout the cell, including nuclei (as evidenced by the DAPI overlay in Figure 2B ). We further confirmed that Pep-1 could facilitate peptide entry into all cell types at high levels (Supplemental Table 2 ) and Pep-1 was thus utilized in subsequent studies.
We next tested whether wild type peptide could compete for the interaction of endogenous SALL4 with HDAC1. SNU-398 cells were treated with wild type or scrambled peptides along with the peptide carrier Pep-1. Binding to HDAC1 by endogenous SALL4 was completely abrogated when cells were treated with the wild type, but not the scrambled peptide ( Figure 2C ).This result demonstrated that wild type peptide can compete with SALL4 in recruiting HDACs.
We then tested whether this peptide could reverse the repressive effect of SALL4 on its target genes. We focused on PTEN, since it is implicated in SALL4mediated leukemogenesis 25, 27 . In addition, we have previously reported that SALL4 could specifically bind to the PTEN promoter region in a chromatin immunoprecipitation (ChIP) assay 27 . When SALL4 was overexpressed in 293T cells, we observed an enrichment of SALL4 as well as decreased H3 acetylation at this binding site, correlated with decreased PTEN RNA expression 27 .
Therefore, we hypothesized that SALL4 could recruit the HDAC/NuRD complex to repress PTEN, and that the wild type peptide would compete with endogenous Figure 3B ). TSA treatment led to a similar anti-proliferative effect on these cancer cells. The effect of wild type peptide is SALL4-specific, as it had no effect on KBM5, an AML cell line with undetectable endogenous SALL4 expression. We were surprised to see that the wild type peptide had no effect on In contrast, treatment of the non-SALL4-expressing KBM5 cells with wild type peptide had little or no effect on the levels of PTEN and pAKT in this cell line ( Figure 3D , right panel) when compared to scrambled peptide treatment. In addition, wt peptide treatment had no effect on endogenous SALL4 expression (Supplemental Figure 3 ).
To further test whether the effect of wild type peptide on tumor cells is related to PTEN, we used a PTEN inhibitor (SF1670) 28 . This PTEN inhibitor does not affect the expression level of PTEN, but can reverse the effect of PTEN on dephosphorylation of its downstream target pAKT 28 . While SALL4-expressing THP1 cells treated with wild type peptide alone showed decreased cell viability, co-treatment with this PTEN inhibitor restored the cell viability to the baseline levels, similar to that of scrambled peptide treatment ( Figure 3E, left panel) . As a control for the specificity of SALL4, we also treated KBM5, a non-SALL4expressing cell line with PTEN inhibitor. Both wild type and scrambled peptide For personal use only. on November 16, 2017. by guest www.bloodjournal.org From treatment showed no change in cell viability, and co-treatment of this PTEN inhibitor with wild type peptide in this cell line showed no effect as well ( Figure 3E , right panel). Results similar to that observed in THP1 were noticed in HCC cell lines such as SNU-398 cells (high SALL4 expression); while SNU-387 cells (with undetectable SALL4 expression) demonstrated a pattern similar to KBM5 cells (data not shown).
In summary, the anti-proliferative effect of this wild type peptide is only observed in SALL4-expressing tumor cells with intact PTEN gene, and can be rescued with a PTEN inhibitor. Combining our observation on the biological effects of the peptide treatment and the expression of PTEN and pAKT in these cells, we conclude that the role of the wild type peptide in promotion of tumor cell death is correlated to its effect on expression levels of PTEN and pAKT, suggesting that at least in part, it is working specifically through the PTEN/AKT pathway.
Treatment of primary AML cells with SALL4 peptide leads to impaired leukemic engraftment in vivo, similar to that of down-regulation of SALL4
We have shown previously that SALL4 is critical for leukemic cell survival in the AML cell line NB4 25 . Here we asked whether this is also the case for primary human AML samples. Three SALL4/PTEN-expressing AML samples were selected for experiments in which cells were first tested under culture conditions that maintain/promote viability of AML cells [29] [30] [31] [32] . The SALL4-specific shRNA that has been validated in our previous studies 12, 25, 33 was utilized in these AML patient samples ( Figure 4A ). 48 hours after transduction, we in the control scrambled shRNA-treated group, decreased viability was observed following reduction of SALL4 expression in primary AML cells in culture (SALL4 shRNA1: 80.9%, N=3, +/-SD=2.75%, P=0.0002; SALL4 shRNA2: 87.3%, N=3, +/-SD=4.59%, P=0.0008; Figure 4B ). Furthermore, in a xenotransplant model, we observed increased survival of leukemic cell recipient NOD/SCID/IL2rγ-null (NSG) mice following knocking down SALL4 expression in the primary AML samples.
To ensure similar viable leukemic cells were given to the recipient mice, early time point engraftment was measured, and showed a similar human leukemic cell engraftment between the control-treated and SALL4 knock-down recipients at 24 hours post transplant. An increased engraftment in controltreated recipient group however, was observed at 48 hours post transplant (Supplemental Figure 4 ) when compared to SALL4 knock-down recipient group.
In the long term follow up study, all recipients receiving AML cells transduced with a scrambled control shRNA (n=7) died within three months while only 2 out of 6 mice receiving SALL4 shRNA-treated primary AML died during the study period ( Figure 4C and Supplemental Table 3 ).
While the median survival of scrambled shRNA control recipient mice (n=7) was 33 days, the median survival of SALL4 shRNA recipient mice (n=6) was 109 days (P=0.01). The transplanted leukemia disease was characterized by For personal use only. on November 16, 2017. by guest www.bloodjournal.org From immature blasts with human CD45 expression in peripheral blood, bone marrow, and tissues such as liver and spleen ( Figure 4D to G). In contrast, non-leukemic SALL4 shRNA recipient mice showed less than 0.5% human CD45 positive cells ( Figure 4H ) in the bone morrow or spleen samples.
We next tested whether we could achieve a therapeutic effect by using the wild type peptide in primary human AML samples. The same SALL4/PTEN expressing primary AML samples were selected for experiments under the same culture conditions as mentioned above. Leukemic cells were subjected to three treatment regimes: peptide (wild type or scrambled), peptide plus PTEN inhibitor, or HDAC inhibitor (TSA). To assist peptide delivery into cells, a carrier agent, Pep-1 was used for all the experiments, and control treated cells were given pep-1 alone (mock). At 96 hours from the commencement of first treatment dose, cellular viability was determined by flow cytometry after staining with Annexin V and PI. We observed a significant decrease in cell viability of primary AML cells after wild type peptide treatment which could be rescued by the PTEN inhibitor SF1670 (Figure 2A ). Cells treated with either scrambled peptide or the Pep-1 peptide carrier (Mock) had over 97% cell viability, similar to that of non-treated cells at the end of the fourth day. However, we observed only 55.3% cell viability upon wild type peptide treatments (N=3, +/-SD=12.02%, P=0.006), which could in part be rescued by the PTEN inhibitor SF1670, which restored cell viability back to 78.3% (N=3, +/-SD=11.7%). Similar to wild type peptide treatment, TSA also induced cell death, with cell viability of 54.7% observed at fourth day posttreatment (N=3, +/-SD=21.6%, P=0.041, Figure 5A ). We subsequently tested the ability of peptide treatment to inhibit the development of AML in vivo utilizing xenografts. Consistent with our cell culture observations, we observed reduced engraftment of human AML cells treated with wild type peptides following xenotransplantation. Pep-1-treated only, or Pep-1 plus wild type or scrambled peptide-treated primary human AML cells were transplanted into sublethally irradiated NSG mice by tail vein injection. To ensure similar viable leukemic cells were given to the recipient mice, early time point engraftment was measured, and showed a similar human leukemic cell engraftment between the scramble peptide treated and wild type peptide treated recipients at 24 hours post transplant. However, at two weeks post transplant, the engraftment from scramble peptide treated recipients was statistically high than that from wild type peptide treated recipients (Supplemental Figure 5) . A long term follow up study was also conducted. 11 weeks after transplantation, Pep-1-alone or scrambled peptide recipient mice became moribund, and all mice were euthanized for analysis ( Figure 5B ). The recipients from either the Pep-1 alone or Pep-1 plus scrambled peptide-treated group had blasts on bone marrow cytospin, splenomegaly, and leukemic infiltration of the kidneys ( Figure 5C&D ). In addition, we evaluated the engraftment of human CD45+ cells by flow cytometry ( Figure 5E ). While the average engraftment of Pep-1 alone or Pep-1 plus scrambled peptide-treated cells was greater than 74% in bone marrow, the average engraftment of the Pep-1 plus wild type peptide-treated group was only 0.5%. Similar differences were observed in spleen and peripheral blood ( Figure   5F ). These results demonstrate that blocking the SALL4 interaction with Targeting the transcription factor(s) that recruits HDACs in cancers could potentially achieve more specific therapeutic effects.
The embryonic stem cell gene SALL4 encodes a zinc finger transcription factor. Its expression is down-regulated during development, and absent in most adult tissues, but aberrantly re-expressed in cancer cells, including AML.
Knocking down the SALL4 gene by shRNA in leukemia and solid tumors leads to cell death and growth inhibition both in vitro and in vivo 13, 25, 33, 47, 48 . The unique expression pattern of SALL4 and its essential functional role for cancer cell survival makes it an ideal candidate for targeting cancer cells.
The important role of transcription factor SALL4 in leukemic stem or initiating cells (LICs) is supported by its interactions with several key players in the self-renewal of embryonic stem cells and LICs, particularly by repression of PTEN expression. We have discovered that SALL4 mainly acts as a repressor by interacting with an epigenetic HDAC/NuRD complex, and that the oncogenic role of SALL4 in cancer development in part is through its repressive function on the tumor suppressor PTEN by recruiting the HDAC/NuRD complex. In this study, we tested whether blocking the SALL4 interaction with the HDAC/NuRD complex could have a biological effect in cancer cells, particular AML cells. We hypothesized that HDAC inhibitors (either by targeting the enzymatic activities of HDAC and/or disrupting the interaction between the HDAC and its transcription factor recruiter) can impair SALL4's repressor function, and negatively affect the self-renewal and survival of leukemic cells by re-activating the expression of PTEN ( Figure 6 ). In this study, we present data that supports this hypothesis.
First, we have demonstrated that the SALL4 HDAC/NuRD recruiting region is located at the N-terminus of SALL4, and contains 12 critical AA. Furthermore, we have shown that this 12-AA peptide has demonstrated growth inhibition of leukemic cells similar to that of classic HDAC inhibitors such as TSA, as well as that of down-regulation of SALL4 gene by shRNA. This supports our proposal While PTEN is being used here as a "proof-of-concept" example for our proposed peptide action model, we expect that other SALL4 target genes may be affected by the peptide as well. We are in the process to perform global expression profiling after the peptide treatment in SALL4-expressing cancers, including AML. Of interest, the expression of SALL4 activated genes, such as cmyc, are not affected by peptide treatment (data no shown).
To test whether targeting SALL4 with this peptide can be used in treating solid tumors, such as HCC, we treated the HCC cell line with wild type and control scrambled and mutant peptides. We found that similar to our observations in AML, treating SALL4-expressing HCC cell lines can lead to cell death in culture and decreased tumorigenesis in murine xenograft models, identical to the phenotype generated by loss-of-function of SALL4 by a shRNA approach (KJ Yong and L. Chai, manuscript under review). These findings suggest targeting SALL4 can be used as an innovative approach in treating solid tumors as well.
While the peptide shows potential for anti-cancer usage, we are also concerned about its potential toxic effects on normal cells, particular hematopoietic stem/progenitor cells. We have treated the selected normal CD34+ cells with this peptide or its controls, and followed by culturing these cells under ex vivo culture condition for 7 to 8 days and transplanted into sublethally irradiated NSG recipients. We have not observed any cytotoxicity so far, such as apoptosis/death of the CD34+ cells during ex vivo culture or a negative impact on in vivo engraftment, after peptide treatment (H Tatetsu and L. Chai, manuscript in preparation). Long-term in vivo effect of this peptide on additional normal tissues is still on going.
Taken together, our studies demonstrate that this peptide can be used as a cell type-specific, SALL4 gene-specific HDAC inhibitor, and/or SALL4/PTEN modulator in cancer treatment. Future studies will focus on optimizing peptide design and/or the development of small molecule peptide mimetics that can specifically block/compete the interaction between SALL4 and the HDAC complex in the treatment of leukemia and other malignancies. We believe that this novel approach, targeting the interaction between a transcription factor (SALL4) and its epigenetic complex (HDAC/NuRD) will serve as a paradigm for targeting other transcription factors in other malignancies, both in solid tumors and leukemia, and thus provide a new direction in targeted cancer therapy. 
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